Brief: Barinthus Bio Reports Second Quarter 2025 Financial Results And Updates On Corporate Developments
07/08/2025 13:16
Aug 7 (Reuters) - Barinthus Biotherapeutics PLC 2ABy.F: BARINTHUS BIO REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND UPDATES ON CORPORATE DEVELOPMENTS BARINTHUS BIOTHERAPEUTICS PLC - CASH RUNWAY GUIDANCE INTO 2027 REMAINS UNCHANGED BARINTHUS BIOTHERAPEUTICS -SINGLE ASCENDING DOSE PART OF PHASE 1 AVALON TRIAL DATA READOUT EXPECTED EARLY Q4 2025 Source text: ID:nGNX9jg2vp Further company coverage: [2ABy.F] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Barinthus Biotherapeutics
See all newsBrief: Barinthus Bio Provides Update On Proposed Combination With Clywedog Therapeutics
Brief: Barinthus Biotherapeutics PLC Appoints Douglas Swirsky As CFO And Principal Accounting Officer Effective May 1, 2026
Brief: Barinthus Bio Announces Update On Phase 1 AVALON Clinical Trial Of VTP-1000 For The Treatment Of Celiac Disease
Brief: Barinthus Bio Reports Second Quarter 2025 Financial Results And Updates On Corporate Developments
Gemma Brown Terminated As CFO Effective April 30, 2025 - SEC Filing